BIO-UV Group (ALTUV) H2 2024 earnings summary

Executive summary

• EBITDA margin increased to 13.5% in 2024, marking the fifth consecutive year of double-digit operational profitability.

• Record free cash flow of €5.0M enabled accelerated net financial debt reduction by €4.7M.

• Revenue declined 8% year-over-year to €39.6M, with stable terrestrial activities and a 27% drop in maritime activities.

• New commercial organization launched in January 2025, splitting operations into Products, Solutions, and Services divisions.

Financial highlights

• EBITDA reached €5.3M in 2024, nearly flat versus €5.5M in 2023; EBITDA margin improved to 13.5% from 12.8%.

• Operating income was €2.1M (5.4% margin), slightly down from €2.3M (5.3%) in 2023.

• Net result was breakeven, but adjusted for a one-time US litigation settlement, net income would have been €0.8M.

• Free cash flow hit a record €5.0M, up from €4.3M in 2023.

• Cash flow from operations rose to €6.9M, up 11% year-over-year.

Outlook and guidance

• Focus in 2025 on resuming organic growth, especially in Solutions and Services, with an emphasis on exports.

• Continued improvement in operational profitability and further debt reduction targeted.

• After recent capital increase, plans for opportunistic external growth, particularly in North America.